The Role of HMMR-AS1 Mediated EMT in Acquired Cisplatin Resistance in Cervical Cancer

doi:10.3969/j.issn.1671-2587.2020.02.018

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2020, Vol. 22 ›› Issue (2): 184-190.DOI: 10.3969/j.issn.1671-2587.2020.02.018

Previous Articles Next Articles

The Role of HMMR-AS1 Mediated EMT in Acquired Cisplatin Resistance in Cervical Cancer

SHU qi, MA Hui-ping, FAN Yang-yang, et al

Department of Gynaecology,Shanxi Nuclear Industry 215 Hospital,Xianyang 712000

Received:2019-02-21 Online:2020-04-20 Published:2020-04-16

Abstract

Abstract: Objective To detect the expression pattern of HMMR-AS1 and its effect on the sensibility of chemotherapy on cervical cancer. Methods qRT-PCR was used to detect the expression of HMMR-AS1 in cervial cancer tissues and para-carcinoma normal tissues and EMT markers in Hela cell lines,the relationship between the clinic characteristics of the cervial cancer patients and the expression level and the relationship between the overall survival time and the expression level were analyzed. The effect of high expression of HMMR-AS1 on the proliferation rate of cervical cancer cells was determined by CCK-8 assay. The effect of high expression of HMMR-AS1 on the sensitivity of cervical cancer cells to cisplatin was determined by chemotherapeutic drug sensitivity test. Results HMMR-AS1 was upregulated in cervical cancer （P=0.03）,high expression of HMMR-AS1 was correlated with the stage （P=0.031）,T （P=0.004）,N （P=0.047）,M （P=0.033）,chemotherapy （P=0.007） and shorter overall survival time （χ²=7.31,P=0.006 9）. Upregulation of HMMR-AS1 promoted Hela cell proliferation （96 h,P=0.002）,migration（P=0.000 65）,invasion（P=0.005 3）,and reduced sensitivity to cisplatin （P=0.003 2）. Conclusion HMMR-AS1 was upregulated in cervical cancer,and HMMR-AS1 could shorten the overall survival time of cervical cancer patients,and lowered the sensibility of chemotherapy on cervical cancer.

Key words: Cervical Cancer, HMMR-AS1, EMT, Cisplatin

CLC Number:

R737.31

SHU qi, MA Hui-ping, FAN Yang-yang, et al. The Role of HMMR-AS1 Mediated EMT in Acquired Cisplatin Resistance in Cervical Cancer[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(2): 184-190.

References

1 Chen W，Sun K，Zheng R，et al. Cancer incidence and mortality in china，2014 [J]. Chin J Cancer Res，2018，30（1）：1-12.
2 Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
3 Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
4 Siegel RL，Miller KD，Jemal A. Cancer statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
5 余慧，张涛红，曾宪玲，等. 1011例子宫颈癌临床病理特征及盆腔淋巴结转移危险因素分析 [J]. 实用妇产科杂志，2018，34（10）：759-762.
6 Liu W，Ma J，Cheng Y，et al. Hmmr antisense rna 1，a novel long noncoding rna，regulates the progression of basal-like breast cancer cells [J]. Breast Cancer Targets and Therapy，2016，8（1）：223-229.
7 王冉冉，董珊珊，龙瀛，等. HMMR-AS1介导EMT在上皮性卵巢癌顺铂获得性耐药中的作用 [J]. 肿瘤药学，2018，8（4）：498-504.
8 Chen L，Ma D，Li Y，et al. Effect of long non-coding RNA PVT1 on cell proliferation and migration in melanoma [J]. Int J Mol Med，2018，41（3）：1275-1282..
9 赵敏，林艳苹，马永慈，等. 云南省肿瘤医院4744例宫颈癌流行病学分析 [J]. 卫生软科学，2018，32（10）：74-77.
10 姜波玲，卢媛. 宫颈癌HPV预防性疫苗的研究进展 [J]. 国际妇产科学杂志，2018，45（5）：527-530.
11 许可葵，王静，刘湘国，等. 2009~2014年湖南省肿瘤登记地区恶性肿瘤发病与死亡分析 [J]. 中国肿瘤，2018，27（10）：738-748.
12 张艳明，姜昭敏，赵静，等. 顺铂联合博来霉素同步放疗治疗晚期宫颈癌的临床疗效 [J]. 中国肿瘤临床与康复，2018，25（10）：1189-1191.
13 汪栋，金岚，王今，等. Malat1在结直肠癌组织细胞中的表达及对化疗敏感性的影响 [J]. 中国医药导报，2016，13（32）：12-16.
14 Harper K L，Sosa M S，Entenberg D，et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer [J]. Nature，2016，540（7634）：588-592.
15 Nong Q，Li S，Wu Y，et al. LncRNA COL1A2-AS1 inhibits the scar fibroblasts proliferation via regulating mir-21/smad7 pathway [J]. Biochem Biophys Res Commun，2018，495（1）：319-324.
16 Fang C，Qiu S，Sun F，et al. Long non-coding RNA HNF1A-AS1 mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA[J]. Cancer Lett，2017，410（1）：50-62.
17 Cesana M，Cacchiarelli D，Legnini I，et al. A long noncoding rna controls muscle differentiation by functioning as a competing endogenous rna [J]. Cell，2011，147（2）：358-369.
18 Heilmann K，Toth R，Bossmann C，et al. Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer [J]. Oncogene，2017，36（46）：6446-6461.
19 Nagano T，Fraser P. No-nonsense functions for long noncoding RNAs [J]. Cell，2011，145（2）：178-181.
20 Hammerle M，Gutschner T，Uckelmann H，et al. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1（IGF2BP1）[J]. Hepatology，2013，58（5）：1703-1712.
21 Guo W，Dong Z，Liu S，et al. Promoter hypermethylation-mediated downregulation of mir-770 and its host gene MEG3，a long non-coding RNA，in the development of gastric cardia adenocarcinoma [J]. Mol Carcinog，2017，56（8）：1924-1934.
22 Chen Z，Liu Z，Yang Y，et al. Long non-coding RNA RAB11B-AS1 prevents osteosarcoma development and progression via its natural antisense transcript RAB11B. [J]. Oncotarget，2018，9（42）：26770-26786.
23 Chu ZP，Dai J，Jia LG，et al. Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer：an independent prognostic factor [J]. Eur Rev Med Pharmacol Sci，2018，22（23）：8145-8150.
24 Li J，Ji X，Wang H. Targeting long noncoding RNA HMMR-AS1 suppresses and radiosensitizes glioblastoma [J]. Neoplasia，2018，20（5）：456-466.

[1]	YAN Xiao-chun, LI Yue, HE Fei-yan, et al. Expression Levels and Clinical Significance of Serum miR-205 and miR-944 in Cervical Cancer Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(1): 95-99.
[2]	ZHOU You-wei, LI Xu-qing, WANG Yan, et al. Investigation of Human Papillomavirus Infection and its Genotypein 6 912 Patients from a Hospital in Hefei,2018 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 596-598.
[3]	GE Fei, LIU Ji-yong, HUANG Shu-wei, et al. Study on the Clinical Significance of Combined Detection of SCC,CEA and CYFRA211 For Cervical Cancer Screening [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 599-603.
[4]	XI Yuan, LIU Yong-jie, LI Xiang-kun. Evaluation of the Level of TSGF,SCC-Ag and CA125 in Peripheral Blood of Patients with Cervical Cancer before Chemotherapy [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(5): 521-523.
[5]	WANG Yun-jie, ZHAO Shao-jie. The MiR-31 and Efficacy of the Combined Chemotherapy of Paclitaxel with Cisplatin: A Retrospective Study in Elderly Females with Ovarian Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(3): 236-238.

The Role of HMMR-AS1 Mediated EMT in Acquired Cisplatin Resistance in Cervical Cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact